Table 1.
Study population characteristics.
| Lp N1115 (n = 51) | Placebo (n = 50) | |
|---|---|---|
| Gender, n (%) | ||
| Male | 24 (47.1) | 24 (48.0) |
| Female | 27 (52.9) | 26 (52.0) |
| Age at enrolment, n (%) | ||
| 6–12 months | 25 (49.0) | 25 (50.0) |
| 13–24 months | 26 (51.0) | 25 (50.0) |
| Solid food intake, n (%) | ||
| Yes | 48 (94.1) | 45 (90.0) |
| No | 3 (5.9) | 5 (10.0) |
| Feeding type within 6 months after birth, n (%) | ||
| Exclusive breastfeeding | 29 (56.9) | 26 (52.0) |
| Mixed feeding | 21 (41.2) | 23 (46.0) |
| Formula feeding | 1 (2.0) | 1 (2.0) |
| Body measurements, mean ± SD | ||
| HAZ | 0.30 ± 0.85 | 0.32 ± 1.02 |
| WAZ | 0.32 ± 1.46 | −0.01 ± 1.24 |
| HCZ | −0.37 ± 1.34 | −0.44 ± 1.27 |
| Fecal pH, mean ± SD | 6.16 ± 0.75 | 6.26 ± 0.84 |
| Biochemical indicators at baseline, median (25th, 75th) | ||
| Saliva cortisol, nmol/L | 2.12 (1.14, 3.44) | 1.54 (1.02, 2.64) |
| Saliva sIgA, mg/g | 0.39 (0.24, 0.74) | 0.35 (0.13, 0.78) |
| Fecal sIgA, mg/g | 2.93 (1.42, 5.65) | 3.36 (1.33, 7.31) |
| Calprotectin, mg/g | 0.03 (0.02, 0.10) | 0.02 (0.01, 0.09) |
| α1-antitrypsin, mg/g | 0.34 (0.27, 0.46) | 0.33 (0.25, 0.40) |
WAZ: weight-for-age Z-score, HAZ: height-for-age Z-score, HCZ: head circumference-for-age Z-score.